ZipChip is a plug-and-play separations platform that optimizes mass spectrometry analysis.
908 Devices announced a joint innovation partnership with Hangzhou Just Biotherapeutics (HJB).
HJB partners with technology developers that can aid in their like-minded goal of developing meaningful therapeutics at lower cost to expand access to medicines in underserved markets. HJB has recently launched a world-class pharmaceutical development facility in Hangzhou, Zhejiang where technologies, including the 908 Devices ZipChip platform, will be integrated into their on-site processes.
"We are searching for analytical tools that can provide higher quality data, get us to results faster, and can be leveraged to reduce overall manufacturing costs. The ZipChip platform is a prime example as it streamlines internal processes and gives us access to data we haven't been able to get before. We believe it will be very impactful to our business," said Dr. Jonathan Zhao, Co-Founder and CEO of HJB.
"We are truly excited about our partnership with HJB and the role 908 Devices can play in their overarching mission to develop vital, accessible medicines," said Dr. Kevin J. Knopp, CEO and Co-Founder of 908 Devices. "HJB is extremely innovative and has a clear vision for how ZipChip can give them the edge they need in all stages of biopharma development and production."